JP2023519100A5 - - Google Patents
Info
- Publication number
- JP2023519100A5 JP2023519100A5 JP2022548596A JP2022548596A JP2023519100A5 JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5 JP 2022548596 A JP2022548596 A JP 2022548596A JP 2022548596 A JP2022548596 A JP 2022548596A JP 2023519100 A5 JP2023519100 A5 JP 2023519100A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975047P | 2020-02-11 | 2020-02-11 | |
| US62/975,047 | 2020-02-11 | ||
| US202063030131P | 2020-05-26 | 2020-05-26 | |
| US63/030,131 | 2020-05-26 | ||
| PCT/US2021/017427 WO2021163170A1 (en) | 2020-02-11 | 2021-02-10 | Anti-acvr1 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519100A JP2023519100A (ja) | 2023-05-10 |
| JPWO2021163170A5 JPWO2021163170A5 (https=) | 2024-02-22 |
| JP2023519100A5 true JP2023519100A5 (https=) | 2024-02-22 |
Family
ID=74860418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548596A Pending JP2023519100A (ja) | 2020-02-11 | 2021-02-10 | 抗ａｃｖｒ１抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11945872B2 (https=) |
| EP (1) | EP4103617A1 (https=) |
| JP (1) | JP2023519100A (https=) |
| KR (1) | KR20220140802A (https=) |
| CN (1) | CN115362175A (https=) |
| AU (1) | AU2021218675A1 (https=) |
| CA (1) | CA3167441A1 (https=) |
| IL (1) | IL295419A (https=) |
| MX (1) | MX2022009769A (https=) |
| WO (1) | WO2021163170A1 (https=) |
| ZA (1) | ZA202208222B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118955715A (zh) | 2018-10-23 | 2024-11-15 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| JP2024532345A (ja) * | 2021-09-03 | 2024-09-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 抗ａｃｖｒ２ａ抗体及びその使用 |
| US20240150474A1 (en) | 2022-10-27 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CA2649770C (en) * | 2006-04-18 | 2017-08-15 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodysplasia ossificans progressiva (fop) |
| US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| JP5642972B2 (ja) | 2007-02-21 | 2014-12-17 | ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| BR112017015661A2 (pt) * | 2015-01-30 | 2018-03-20 | Saitama Medical University | anticorpo anti-alk2 |
| CA3093205A1 (en) | 2018-03-05 | 2019-09-12 | Saitama Medical University | Pharmaceutical composition for treating or preventing heterotopic ossification |
| MX2021000977A (es) * | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
| CN118955715A (zh) * | 2018-10-23 | 2024-11-15 | 科乐斯疗法公司 | Alk2抗体及其使用方法 |
| US12428484B2 (en) * | 2018-12-06 | 2025-09-30 | Alexion Pharmaceuticals, Inc. | Anti-ALK2 antibodies and uses thereof |
| JP7668013B2 (ja) * | 2019-07-26 | 2025-04-24 | 学校法人 埼玉医科大学 | Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体 |
-
2021
- 2021-02-10 CN CN202180027355.8A patent/CN115362175A/zh active Pending
- 2021-02-10 JP JP2022548596A patent/JP2023519100A/ja active Pending
- 2021-02-10 AU AU2021218675A patent/AU2021218675A1/en active Pending
- 2021-02-10 KR KR1020227031475A patent/KR20220140802A/ko active Pending
- 2021-02-10 MX MX2022009769A patent/MX2022009769A/es unknown
- 2021-02-10 IL IL295419A patent/IL295419A/en unknown
- 2021-02-10 WO PCT/US2021/017427 patent/WO2021163170A1/en not_active Ceased
- 2021-02-10 EP EP21710676.4A patent/EP4103617A1/en active Pending
- 2021-02-10 US US17/172,856 patent/US11945872B2/en active Active
- 2021-02-10 CA CA3167441A patent/CA3167441A1/en active Pending
-
2022
- 2022-07-22 ZA ZA2022/08222A patent/ZA202208222B/en unknown
-
2024
- 2024-02-22 US US18/584,551 patent/US20240190974A1/en active Pending